Business
Resverlogix Confirms the Completion of Full Debenture Repurchase
Resverlogix Confirms the Completion of Full Debenture Repurchase
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nJan. 7, 2010 (Canada NewsWire Group) -- CALGARY, Jan. 7 /CNW/ -- Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) announced today that it has completed the previously announced redemption of the outstanding convertible notes 2.5 years prior to maturity. On November 18, 2009 the Company announced that the Board of Directors approved a plan to authorize the Company to repurchase the outstanding convertible notes. Today, Resverlogix confirms that a total of US $6.728 million of convertible debt, due June 6, 2012, has been redeemed.About Resverlogix Corp.Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words \"believes\", \"anticipates\", \"plans\", \"intends\", \"will\", \"should\", \"expects\", \"continue\", \"estimate\", \"forecasts\" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with future financings, the success of research and development pr...